復星醫藥(02196.HK):控股子公司獲藥品註冊申請受理
格隆匯7月11日丨復星醫藥(02196.HK)公佈,近日,公司控股子公司上海朝暉藥業有限公司就複方聚乙二醇電解質散(Ⅱ)(以下簡稱“該藥品”)的藥品註冊申請獲國家藥品監督管理局受理。
複方聚乙二醇電解質散(Ⅱ)系化學藥品,擬用於結腸鏡檢查、鋇灌腸X射線造影和結腸直腸手術前預處理中腸道內容物的排出。
截至2025年5月,本集團(即本公司及控股子公司/單位,下同)現階段針對包括該藥品在內的複方聚乙二醇電解質散系列藥品的累計研發投入約爲人民幣474萬元(未經審計)。
根據IQVIACHPA最新數據,2024年,複方聚乙二醇電解質散(Ⅱ)於中國境內(不包括港澳臺地區)的銷售額約爲人民幣3.07億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.